申请人:——
公开号:US20020082250A1
公开(公告)日:2002-06-27
This invention relates to a method of treating or reducing cell proliferation in a mammal in need thereof which comprises administering to said mammal an effective CoA-independent transacylase (CoA-IT) inhibiting amount of a compound of formula (I), wherein the variables of Y, X, m, R 3, R 4, R 10, R 20, R 5, R 6 and R 7 are defined in the specification. FIG.
3
demonstrates the ability of SB216754, ((3S,4R)-4-(isobutenyloxy)-3-triphenylmethylamino)azetidin-2-one) to decrease the viability of HL-60 cells.
这项发明涉及一种治疗或减少哺乳动物细胞增殖的方法,包括向该哺乳动物施用化合物(I)的有效CoA独立转酰基酶(CoA-IT)抑制量,其中化合物的Y、X、m、R 3、R 4、R 10、R 20、R 5、R 6和R 7的变量在说明书中定义。图3展示了SB216754((3S,4R)-4-(异丁烯氧基)-3-三苯甲基氨基)吖唑啉-2-酮)降低HL-60细胞存活能力的能力。